ABBVIE
- Country
- π«π·France
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 64
- Registration Number
- NCT02486406
- Locations
- π΅π·
San Jorge Children Hospital /ID# 136832, San Juan, Puerto Rico
πΊπΈSeattle Children's Hospital /ID# 137019, Seattle, Washington, United States
π©πͺHelios Klinikum Wuppertal /ID# 142883, Wuppertal, Germany
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT02487199
Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients
- Conditions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 88
- Registration Number
- NCT02485600
- Locations
- π¨π¦
Hamilton Health Sciences /ID# 148808, Hamilton, Ontario, Canada
π¨π¦St. Boniface Clinic, CA /ID# 162092, Winnipeg, Manitoba, Canada
π¨π¦Kingston General Hospital /ID# 144942, Kingston, Ontario, Canada
Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT02483104
- Locations
- π―π΅
Site Reference ID/Investigator# 128815, Kurume-shi,Fukuoka, Japan
π―π΅Site Reference ID/Investigator# 128058, Nagaizumi-cho, Japan
π―π΅Site Reference ID/Investigator# 128997, Morioka-shi, Japan
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT02476617
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1140
- Registration Number
- NCT02470585
- Locations
- πΊπΈ
Sinai Hospital of Baltimore /ID# 141306, Baltimore, Maryland, United States
πΊπΈThe Ohio State University - Columbus /ID# 138053, Columbus, Ohio, United States
πΊπΈFox Chase Cancer Center /ID# 149479, Philadelphia, Pennsylvania, United States
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 74
- Registration Number
- NCT02462525
- Locations
- πΊπΈ
Washington University School of Medicine /ID# 135708, Saint Louis, Missouri, United States
πΊπΈMount Sinai Medical Center /ID# 133569, New York, New York, United States
πΊπΈThe University of Chicago Medical Center /ID# 139403, Chicago, Illinois, United States
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
- Conditions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 168
- Registration Number
- NCT02451839
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 141
- Registration Number
- NCT02446717
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 222
- Registration Number
- NCT02442271